Literature DB >> 11461941

Involvement of the activin-follistatin system in tubular regeneration after renal ischemia in rats.

Akito Maeshima1,2, You-Qing Zhang1, Yoshihisa Nojima2, Takuji Naruse2, Itaru Kojima1.   

Abstract

This study was conducted to investigate the involvement of the activin-follistatin system in renal regeneration after ischemic injury. Expression of mRNA for the activin beta(A) subunit was not detected in normal kidneys but increased markedly after renal ischemia. Immunoreactive beta(A) subunit was detected in tubular cells of the outer medulla in ischemic but not normal kidneys. Expression of mRNA for follistatin, an antagonist of activin A, was abundant in tubular cells of the outer medulla in normal kidneys and decreased significantly after renal ischemia. For assessment of the role of the activin-follistatin system in renal regeneration after ischemic injury, recombinant follistatin was intravenously infused into rats with renal ischemia, at the time of reperfusion. Exogenous follistatin prevented the histologic changes induced by ischemic injury, reduced apoptosis in tubular cells, and accelerated tubular cell proliferation. Serum levels of creatinine and blood urea nitrogen were significantly lower in follistatin-treated rats. Conversely, intravenous administration of recombinant activin A inhibited tubular cell proliferation after ischemic injury. These results indicate that the activin-follistatin system participates in renal regeneration after ischemic injury. Follistatin administered intravenously accelerates renal regeneration after renal ischemia, presumably by blocking the actions of endogenous activin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461941     DOI: 10.1681/ASN.V1281685

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  23 in total

1.  GDF11 induces kidney fibrosis, renal cell epithelial-to-mesenchymal transition, and kidney dysfunction and failure.

Authors:  Marianne Pons; Leonidas G Koniaris; Sharon M Moe; Juan C Gutierrez; Aurora Esquela-Kerscher; Teresa A Zimmers
Journal:  Surgery       Date:  2018-05-03       Impact factor: 3.982

2.  Blockade of ALK4/5 signaling suppresses cadmium- and erastin-induced cell death in renal proximal tubular epithelial cells via distinct signaling mechanisms.

Authors:  Kota Fujiki; Hisako Inamura; Takeshi Sugaya; Masato Matsuoka
Journal:  Cell Death Differ       Date:  2019-02-25       Impact factor: 15.828

3.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

4.  Peptide nanofibers preconditioned with stem cell secretome are renoprotective.

Authors:  Yin Wang; Erica Bakota; Benny H J Chang; Mark Entman; Jeffrey D Hartgerink; Farhad R Danesh
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

5.  Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells.

Authors:  Deh-Ming Chang; Shao-Hsiang Liu; Herng-Sheng Lee; Jenn-Hung Lai; Chen-Hung Chen
Journal:  Rheumatol Int       Date:  2007-04-14       Impact factor: 2.631

6.  Beneficial effects of follistatin in hepatic ischemia-reperfusion injuries in rats.

Authors:  Mami Kanamoto; Mitsuo Shimada; Yuji Morine; Tomoharu Yoshizumi; Satoru Imura; Toru Ikegami; Hiroki Mori; Yusuke Arakawa
Journal:  Dig Dis Sci       Date:  2010-09-08       Impact factor: 3.199

7.  Application of regenerative medicine for kidney diseases.

Authors:  Takashi Yokoo; Akira Fukui; Eiji Kobayashi
Journal:  Organogenesis       Date:  2007-01       Impact factor: 2.500

8.  Upregulation of activin signaling in experimental colitis.

Authors:  You-Qing Zhang; Silvia Resta; Barbara Jung; Kim E Barrett; Nora Sarvetnick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-30       Impact factor: 4.052

Review 9.  Label-retaining cells in the kidney: origin of regenerating cells after renal ischemia.

Authors:  Akito Maeshima
Journal:  Clin Exp Nephrol       Date:  2007-12-21       Impact factor: 2.801

Review 10.  Regenerative medicine for the kidney: renotropic factors, renal stem/progenitor cells, and stem cell therapy.

Authors:  Akito Maeshima; Masao Nakasatomi; Yoshihisa Nojima
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.